Aurobindo hires ex-Shasun CEO; eyes more deals with multinationals
This article was originally published in Scrip
Aurobindo Pharma, which has recently announced a string of supply alliances with large multinationals, has secured a top-level executive for its active pharmaceutical ingredients (API) and custom research and manufacturing services (CRAMS) operations.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.